Riboswitch sensors to detect clinical biomarkers
This technology is a set of riboswitch sequences tailored to sense creatine, urea, potassium, lithium, and sodium.
Unmet Need: Real-time monitoring of drug elimination for patients with acute kidney injury
Sepsis is the leading cause of acute kidney injury (AKI) in hospitals, resulting in a mortality rate of >60%. A method is needed to appropriately dose medications, including life-saving antibiotics, in patients with renal damage and relatedly highly variable drug clearance rates.
The Technology: Electrochemical aptamer-based sensors to monitor drug elimination
This technology comprises a set of riboswitch aptamer sequences designed to sense creatine, urea, potassium, lithium, and sodium, for use in electrochemical aptamer-based sensors for monitoring drug elimination during continuous renal replacement therapy. This system provides real-time information on extracorporeal clearance, enabling clinicians to make immediate, informed adjustments to antibiotic dosing.
Applications:
- Monitoring of drug elimination in patients with renal damage
- Detection of metabolic biomarkers for screening, diagnosis, and monitoring
- Precision medicine tool to tailor treatments based on individual metabolic profiles
- Drug screening
Advantages:
- Real-time drug monitoring
- Enables rapid, personalized adjustment of antibiotic dosage
- Multi-target detection of off-target metabolic effects or accumulation of toxic intermediates
Lead Inventor:
Patent Information:
Patent Pending
Related Publications:
Tech Ventures Reference:
IR CU25097
Licensing Contact: Jerry Kokoshka